CSNK2B Antibody

What is CSNK2B and why is it a significant target for antibody-based research?

CSNK2B (Casein Kinase 2 Beta) is the regulatory subunit of casein kinase 2 that functions in cell proliferation and protein phosphorylation regulation. The human version consists of 215 amino acid residues with a molecular mass of approximately 24.9 kDa and is widely expressed across multiple tissue types . CSNK2B is particularly important in research because:

• It participates in Wnt signaling pathways

• It regulates the basal catalytic activity of the alpha subunit

• It functions in multiple cellular processes including viral defense mechanisms

• Recent studies have identified its role in modulating IRF1 (Interferon Regulatory Factor 1) binding to functional DNA elements

This multifunctional nature makes CSNK2B antibodies essential tools for studying protein-protein interactions, signaling pathways, and disease mechanisms.

Which applications are most common for CSNK2B antibody detection methods?

Based on current research protocols, the most widely used applications for CSNK2B antibody detection include:

Western Blot is particularly favored as it allows visualization of the target protein at the expected molecular weight (25-30 kDa for CSNK2B), providing confirmation of antibody specificity .

How should researchers select the appropriate CSNK2B antibody for their specific experimental needs?

Selection of the optimal CSNK2B antibody should be based on:

• Target epitope consideration: Different antibodies recognize distinct regions of CSNK2B. For instance, some antibodies target the C-terminal region (aa 172-186) , while others target phosphorylation sites like S205 or S209 .

• Species reactivity: Verify cross-reactivity with your experimental model. Many CSNK2B antibodies react with human, mouse, and rat proteins, but specificity varies between products .

• Application compatibility: Ensure the antibody is validated for your intended application. For example:

  • For phosphorylation studies, use phospho-specific antibodies (e.g., Anti-Phospho-Casein Kinase I beta S209)

  • For immunoprecipitation experiments, confirm the antibody has been validated for IP

  • For multiple applications, select antibodies validated across your required techniques

• Clonality considerations:

  • Monoclonal antibodies (e.g., 67866-1-Ig) offer high specificity for a single epitope

  • Polyclonal antibodies provide broader detection but may have higher background

• Validation status: Review published literature citing the antibody and examine validation data, including knockout/knockdown controls .

What are the optimal protocols for sample preparation when conducting Western blot analysis with CSNK2B antibodies?

For optimal Western blot results with CSNK2B antibodies:

• Cell/tissue lysis:

  • Use RIPA buffer supplemented with protease inhibitors and phosphatase inhibitors (critical when studying phosphorylated forms of CSNK2B)

  • For phospho-specific detection, add sodium fluoride (10 mM) and sodium orthovanadate (1 mM)

  • Maintain samples at 4°C throughout processing

• Protein quantification:

  • Use Bradford or BCA assay to normalize loading (20-40 μg total protein per lane is typically sufficient)

• Sample denaturation:

  • Mix with Laemmli buffer containing 5% β-mercaptoethanol

  • Heat at 95°C for 5 minutes (avoid excessive heating which may cause aggregation)

• Gel electrophoresis conditions:

  • 10-12% SDS-PAGE gels provide optimal resolution for CSNK2B (25-30 kDa)

  • Run at 100-120V to ensure proper band resolution

• Transfer parameters:

  • Use PVDF membrane (0.2 μm pore size) for optimal protein retention

  • Transfer at 100V for 60-90 minutes or 30V overnight at 4°C

• Blocking:

  • 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

  • For phospho-specific antibodies, BSA is preferred over milk

• Antibody incubation:

  • Primary antibody dilutions according to manufacturer recommendations (e.g., 1:1000-1:6000 for CSNK2B)

  • Incubate overnight at 4°C with gentle agitation

• Positive controls:

  • Include lysates from cell lines known to express CSNK2B, such as HeLa, HepG2, NIH/3T3, K-562, or MCF-7 cells

How can CSNK2B antibodies be utilized to investigate its role in IRF1-mediated antiviral responses?

Recent research has uncovered CSNK2B's critical role in modulating IRF1 transcriptional activity and antiviral defense . To investigate this pathway:

• Protein-protein interaction studies:

  • Co-immunoprecipitation: Use anti-CSNK2B antibodies to pull down protein complexes and probe for IRF1

  • Proximity ligation assay: Visualize CSNK2B-IRF1 interactions in situ using specific antibodies

• Chromatin immunoprecipitation approaches:

  • CUT&RUN assay: As demonstrated in recent research, use IRF1 antibodies in CSNK2B-depleted versus control cells to map genome-wide binding sites

  • Method details: "CUT&RUN was performed on 5 × 10^5 PH5CH8 cells transfected with CSNK2B versus non-target control siRNAs using CUT&RUN Assay Kit (Cell Signaling Technology, #86652)" with IRF1 antibody (1:25 dilution)

• Functional validation experiments:

  • Gene knockdown: Use siRNA to deplete CSNK2B and assess effects on IRF1 target gene expression

  • CRISPR-Cas9 approach: Generate CSNK2B knockout cell pools to evaluate antiviral responses

  • HAV infection model: Challenge cells with hepatitis A virus following CSNK2B depletion to assess viral replication

• Primary cell validation:

  • Use primary human hepatocytes (PHHs) with CSNK2B knockdown

  • Include JAK inhibitors (e.g., pyridone 6) to diminish induced IFN responses and isolate constitutive defense mechanisms

This experimental workflow elucidated how CSNK2B enhances IRF1 binding to chromatin, promoting transcription of antiviral genes like PLAAT4, while preventing abnormal IRF1 accumulation at other loci like AFAP1 .

What are the key considerations when investigating phosphorylation-specific forms of CSNK2B?

CSNK2B phosphorylation status is critically important for its function. When investigating phosphorylated forms:

• Selection of phospho-specific antibodies:

  • Use antibodies targeting specific phosphorylation sites such as S205 or S209

  • Verify antibody specificity using phosphatase treatments as negative controls

• Sample preparation considerations:

  • Immediate lysis is crucial to preserve phosphorylation status

  • Include phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate) in all buffers

  • Maintain samples at 4°C throughout processing

• Controls for phosphorylation studies:

  • Lambda phosphatase treatment: "Lambda protein phosphatase was obtained from Bio Academia" and can be used to remove phosphate groups as a negative control

  • Phosphomimetic mutants: Generate S→E or S→D mutations to mimic phosphorylation

  • Phospho-null mutants: Generate S→A mutations to prevent phosphorylation

• Kinase inhibition experiments:

  • CX-4945 (Silmitasertib) can be used to inhibit CK2 activity

  • Monitor effects on CSNK2B phosphorylation and downstream signaling

• Mass spectrometry validation:

  • For unbiased detection of phosphorylation sites, perform phospho-enrichment followed by LC-MS/MS

  • This approach can identify novel phosphorylation sites beyond those targeted by available antibodies

How can researchers address common issues with non-specific binding when using CSNK2B antibodies?

Non-specific binding is a common challenge when working with CSNK2B antibodies. To improve specificity:

• Antibody selection considerations:

  • Compare monoclonal (e.g., 67866-1-Ig) versus polyclonal antibodies (e.g., 22418-1-AP)

  • Review validation data showing antibody specificity in knockout/knockdown samples

• Blocking optimization:

  • Test different blocking agents (5% BSA, 5% non-fat milk, commercial blocking buffers)

  • Extend blocking time to 2 hours at room temperature or overnight at 4°C

• Antibody dilution optimization:

  • Perform titration experiments with serial dilutions (e.g., 1:500, 1:1000, 1:2000, 1:5000)

  • Follow manufacturer's recommended ranges (e.g., 1:1000-1:6000 for WB)

• Washing stringency:

  • Increase washing duration and number of washes (5-6 washes of 5-10 minutes each)

  • Test different detergent concentrations in wash buffer (0.05%-0.1% Tween-20)

• Positive and negative controls:

  • Include CSNK2B knockdown or knockout samples as negative controls

  • Use HeLa, HepG2, NIH/3T3, K-562, or MCF-7 cells as positive controls

• Cross-reactivity assessment:

  • Verify the observed band matches the expected molecular weight (25-30 kDa for CSNK2B)

  • Consider using multiple antibodies targeting different CSNK2B epitopes to confirm results

What methodological approaches should be used to verify the specificity of CSNK2B antibodies in novel experimental systems?

To validate CSNK2B antibody specificity in new experimental systems:

• Genetic validation approaches:

  • siRNA knockdown: Transfect cells with CSNK2B-specific siRNAs and confirm signal reduction

  • CRISPR/Cas9 knockout: Generate CSNK2B knockout cell lines as definitive negative controls

  • Overexpression systems: Transfect cells with tagged CSNK2B and confirm co-localization with antibody signal

• Peptide competition assays:

  • Pre-incubate antibody with immunizing peptide or recombinant CSNK2B protein

  • Signal should be significantly reduced or eliminated in the presence of competing antigen

• Multiple antibody validation:

  • Test different antibodies targeting distinct CSNK2B epitopes

  • Consistent signals across antibodies increase confidence in specificity

• Cross-species reactivity testing:

  • Compare antibody performance across species (human, mouse, rat) if your research involves multiple models

  • Confirm reactivity matches predicted conservation of the epitope sequence

• Western blot molecular weight verification:

  • Confirm band appears at the expected molecular weight (25-30 kDa)

  • Be aware of potential post-translational modifications that may alter migration

• Mass spectrometry confirmation:

  • Perform immunoprecipitation followed by mass spectrometry to confirm antibody pulls down CSNK2B

  • This approach can also identify binding partners and post-translational modifications

How does CSNK2B contribute to antiviral immunity and what methodologies can best demonstrate this function?

Recent research has revealed CSNK2B's significant role in antiviral defense mechanisms . To investigate this function:

• IRF1-CSNK2B interaction studies:

  • Co-immunoprecipitation to confirm direct protein interaction

  • Proximity ligation assay for in situ visualization of interactions

  • Domain mapping to identify interaction interfaces

• Transcriptional regulation analysis:

  • CUT&RUN assay to map genome-wide IRF1 binding sites in CSNK2B-sufficient versus deficient cells

  • RNA-seq to identify CSNK2B-dependent gene expression changes

  • ChIP-qPCR to validate binding to specific promoters (e.g., PLAAT4)

• Functional antiviral assays:

  • Viral challenge experiments with HAV in cells with CSNK2B knockdown/knockout

  • Quantification of viral RNA by RT-qPCR and infectious virus production

  • Primary human hepatocyte model with JAK inhibition to isolate constitutive defense

• AFAP1-Src signaling analysis:

  • Western blot for phospho-Src (Y416) following CSNK2B depletion

  • Cytoskeletal organization assessment following DENV infection

  • Combined knockdown of CSNK2B and AFAP1 to assess epistatic relationships

The experimental evidence demonstrates that "CSNK2B acts generally to enhance the binding of IRF1 to chromatin, thereby enhancing transcription of key antiviral genes" and that CSNK2B "mediates phosphorylation-dependent activation of AFAP1-Src signaling and exerts suppressive effects against flaviviruses, including dengue virus" .

What role does CSNK2B play in intellectual disability disorders and how can researchers investigate pathogenic variants?

De novo variants of CSNK2B have been associated with a newly described intellectual disability-craniodigital syndrome . Research methodologies to investigate these variants include:

• Genetic analysis approaches:

  • Whole-exome sequencing to identify CSNK2B variants in affected individuals

  • Copy number analysis to detect larger structural variations

  • In silico pathogenicity prediction using multiple tools

• Structural impact assessment:

  • Protein modeling to visualize variant location within CK2α/β complex

  • Conservation analysis by aligning ortholog sequences from multiple species

  • Molecular dynamics simulations to predict effects on protein stability

• Functional characterization:

  • Generation of patient-derived lymphoblastoid cell lines (LCLs)

  • Immunofluorescence to assess protein localization: "After permeabilization with 0.5% Triton X-100, cells were blocked in 5% FBS for 1 hour"

  • Western blot analysis to assess expression levels and complex formation

• Wnt signaling assessment:

  • TOPFlash luciferase reporter assays to measure canonical Wnt signaling

  • β-catenin localization studies in patient cells versus controls

  • Rescue experiments with wild-type CSNK2B expression

• Phenotypic analysis:

  • GestaltMatcher analysis for facial phenotype comparison among individuals with CSNK2B variants

  • Neurodevelopmental assessments in patient cohorts

  • Morphological analysis of craniofacial and digital features

This multidisciplinary approach enables researchers to establish clear genotype-phenotype correlations and understand the molecular mechanisms by which CSNK2B variants lead to neurodevelopmental disorders.